肾癌十年回顾：发现、治疗与机遇
Decade in review-kidney cancer: discoveries, therapies and opportunities.
作者信息
Linehan W Marston, Ricketts Christopher J
机构信息
Urologic Oncology Branch, National Cancer Institute, 10 Center Drive, MSC 1107, CRC Room 1W-5940, Bethesda, MD 20892-1107, USA.
出版信息
Nat Rev Urol. 2014 Nov;11(11):614-6. doi: 10.1038/nrurol.2014.262. Epub 2014 Oct 7.
Abstract
Advances in kidney cancer have occurred over the past decade, including the discovery of mutations in chromatin remodeling genes and genomic heterogeneity in clear cell renal cell carcinoma (ccRCC), altered metabolic patterns in ccRCC and papillary renal cell carcinoma and the approval of drugs for patients with ccRCC.
摘要
在过去十年中，肾癌研究取得了进展，包括在染色质重塑基因中发现突变以及在透明细胞肾细胞癌（ccRCC）中发现基因组异质性，ccRCC和乳头状肾细胞癌中代谢模式的改变，以及ccRCC患者药物的获批。
相似文献
1
Decade in review-kidney cancer: discoveries, therapies and opportunities.肾癌十年回顾：发现、治疗与机遇
Nat Rev Urol. 2014 Nov;11(11):614-6. doi: 10.1038/nrurol.2014.262. Epub 2014 Oct 7.
2
Targeting SPOP with small molecules provides a novel strategy for kidney cancer therapy.用小分子靶向SPOP为肾癌治疗提供了一种新策略。
Sci China Life Sci. 2017 Jan;60(1):91-93. doi: 10.1007/s11427-016-0297-2. Epub 2016 Nov 23.
3
Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.肾细胞癌分子靶向治疗的预测性生物标志物
J Natl Compr Canc Netw. 2016 Jul;14(7):925-7. doi: 10.6004/jnccn.2016.0095.
4
What's new in renal cell carcinoma.肾细胞癌有哪些新进展。
Bull Am Coll Surg. 2012 Aug;97(8):65-6.
5
[Targeted therapy for renal cell carcinoma].[肾细胞癌的靶向治疗]
Nihon Jinzo Gakkai Shi. 2016;58(4):568-72.
6
Targeted therapies: another option for metastatic RCC.靶向治疗：转移性肾细胞癌的另一种选择。
Nat Rev Clin Oncol. 2013 Nov;10(11):607. doi: 10.1038/nrclinonc.2013.175. Epub 2013 Sep 24.
7
[Research impulses for personalized cancer therapies].[个性化癌症治疗的研究动力]
Aktuelle Urol. 2013 Sep;44(5):349. doi: 10.1055/s-0033-1353705. Epub 2013 Sep 16.
8
Genetic and metabolic hallmarks of clear cell renal cell carcinoma.透明细胞肾细胞癌的遗传和代谢特征。
Biochim Biophys Acta Rev Cancer. 2018 Aug;1870(1):23-31. doi: 10.1016/j.bbcan.2018.06.003. Epub 2018 Jun 28.
9
MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.与肾细胞癌中 von Hippel-Lindau 通路相关的 microRNAs：全面综述。
Int J Mol Sci. 2017 Nov 22;18(11):2495. doi: 10.3390/ijms18112495.
10
What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality?我们需要做些什么才能将基于基因生物标志物的肾细胞癌治疗变为现实？
Pharmacogenomics. 2017 Jan;18(1):1-4. doi: 10.2217/pgs-2016-0168. Epub 2016 Dec 14.
引用本文的文献
1
DOK1 facilitates the advancement of ccRCC.DOK1促进透明细胞肾细胞癌的进展。
J Cancer. 2024 Oct 14;15(19):6213-6222. doi: 10.7150/jca.104375. eCollection 2024.
2
ISG15 promotes tumor progression via IL6/JAK2/STAT3 signaling pathway in ccRCC.ISG15 通过 IL6/JAK2/STAT3 信号通路促进 ccRCC 肿瘤进展。
Clin Exp Med. 2024 Jun 29;24(1):140. doi: 10.1007/s10238-024-01414-z.
3
Prognostic value of neutrophil extracellular trap signature in clear cell renal cell carcinoma.中性粒细胞胞外诱捕网特征在透明细胞肾细胞癌中的预后价值
Front Oncol. 2023 Jul 13;13:1205713. doi: 10.3389/fonc.2023.1205713. eCollection 2023.
4
P4HA3 promotes clear cell renal cell carcinoma progression via the PI3K/AKT/GSK3β pathway.P4HA3通过PI3K/AKT/GSK3β信号通路促进肾透明细胞癌进展。
Med Oncol. 2023 Jan 2;40(2):70. doi: 10.1007/s12032-022-01926-2.
5
Pyroptosis-Related Gene Signature Predicts the Prognosis of ccRCC Using TCGA and Single-Cell RNA Seq Database.基于 TCGA 和单细胞 RNA 测序数据库的焦亡相关基因特征预测 ccRCC 的预后。
J Healthc Eng. 2022 Oct 30;2022:8224618. doi: 10.1155/2022/8224618. eCollection 2022.
6
Comprehensive analysis of expression and prognostic value in kidney renal papillary cell carcinoma and clear cell carcinoma.肾乳头状细胞癌和透明细胞癌中表达及预后价值的综合分析。
Front Mol Biosci. 2022 Sep 16;9:988777. doi: 10.3389/fmolb.2022.988777. eCollection 2022.
7
The Correlation of HK2 Gene Expression with the Occurrence, Immune Cell Infiltration, and Prognosis of Renal Cell Carcinoma.HK2 基因表达与肾细胞癌发生、免疫细胞浸润及预后的相关性。
Dis Markers. 2022 Feb 27;2022:1452861. doi: 10.1155/2022/1452861. eCollection 2022.
8
MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma.形态学异质性透明细胞肾细胞癌的微小RNA分析
J Cancer. 2021 Jul 6;12(18):5375-5384. doi: 10.7150/jca.52310. eCollection 2021.
9
Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma.BCL2L13的下调在透明细胞和乳头状肾细胞癌中提示预后不良。
Cancer Cell Int. 2021 Jun 30;21(1):332. doi: 10.1186/s12935-021-02039-y.
10
Silencing of the Gene by Aberrant Promoter Methylation is Associated with a Poor Patient Outcome and Promotes Cell Proliferation and Migration in Clear Cell Renal Cell Carcinoma.异常启动子甲基化导致的该基因沉默与患者预后不良相关，并促进透明细胞肾细胞癌的细胞增殖和迁移。
Front Mol Biosci. 2021 Mar 16;8:655126. doi: 10.3389/fmolb.2021.655126. eCollection 2021.
本文引用的文献
1
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing.多区域测序定义的透明细胞肾细胞癌的基因组结构和演化。
Nat Genet. 2014 Mar;46(3):225-233. doi: 10.1038/ng.2891. Epub 2014 Feb 2.
2
Comprehensive molecular characterization of clear cell renal cell carcinoma.透明细胞肾细胞癌的全面分子特征分析。
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23.
3
Ten years of progress in renal cell carcinoma.肾细胞癌十年进展
J Natl Compr Canc Netw. 2012 Jun 1;10(6):690-3. doi: 10.6004/jnccn.2012.0071.
4
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.IDH1 介导的还原性谷氨酰胺代谢在低氧条件下促进脂肪生成。
Nature. 2011 Nov 20;481(7381):380-4. doi: 10.1038/nature10602.
5
Reductive carboxylation supports growth in tumour cells with defective mitochondria.还原羧化作用为线粒体功能缺陷的肿瘤细胞生长提供支持。
Nature. 2011 Nov 20;481(7381):385-8. doi: 10.1038/nature10642.
6
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling.Fh1 缺陷型小鼠肾囊肿的形成不依赖于 Hif/Phd 通路：富马酸盐在 KEAP1 琥珀酰化和 Nrf2 信号中的作用。
Cancer Cell. 2011 Oct 18;20(4):524-37. doi: 10.1016/j.ccr.2011.09.006.
7
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma.遗传性和散发性 2 型乳头状肾细胞癌之间存在抗氧化反应表型。
Cancer Cell. 2011 Oct 18;20(4):511-23. doi: 10.1016/j.ccr.2011.08.024.
8
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels.琥珀酸脱氢酶缺乏型肾细胞癌中的糖酵解转换会降低 AMPK 水平，增加合成代谢倾向，并降低细胞内铁水平。
Cancer Cell. 2011 Sep 13;20(3):315-27. doi: 10.1016/j.ccr.2011.07.018.
9
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma.外显子组测序鉴定出肾癌中 SWI/SNF 复合物基因 PBRM1 的高频突变。
Nature. 2011 Jan 27;469(7331):539-42. doi: 10.1038/nature09639. Epub 2011 Jan 19.
10
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.系统测序肾细胞癌揭示组蛋白修饰基因失活。
Nature. 2010 Jan 21;463(7279):360-3. doi: 10.1038/nature08672. Epub 2010 Jan 6.
Zotero 插件